Plasma Fractionation Market (Product Type: Immunoglobulin, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, and Other Plasma Products) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031
혈장 분획 시장 - 조사 범위
TMR의 세계 혈장 분획 시장 조사 보고서는 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고, 2023년을 기준 연도로, 2031년을 예측 연도로, 2017에서 2031년까지 세계 혈장 분획 시장의 수익과 예측을 제공합니다. 또한 2023년부터 2031년까지 세계 혈장 분획 시장의 복합 연간 성장률(CAGR%)도 제공합니다.
이 보고서는 광범위한 조사 끝에 작성되었습니다. 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료 및 관련 문서를 참조하여 혈장 분획 시장을 이해하고자 했습니다. 참고했습니다.
| 시장 현황 |
| 2022년 시장 가치 |
241억 달러 |
| 2031년 시장 가치 |
426억 달러 |
| CAGR |
6.7% |
이 보고서는 세계 혈장 분획 시장 경쟁 구도를 심층적으로 분석합니다. 세계 혈장 분획 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 시장 개발 및 SWOT는 이 보고서에서 다루는 세계 혈장 분획 시장의 기업 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 혈장 분획 시장
제4장 시장 개요
- 서론
- 시장 개요
- 시장 역학
- 혈장 분획 시장 분석과 예측, 2017-2031년
제5장 주요 인사이트
- 파이프라인 분석
- 주요 기술/브랜드 분석
- 주요 M&A
- COVID-19 팬데믹 업계에 대한 영향
제6장 혈장 분획 시장 분석과 예측 : 제품 유형별
- 서론과 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 제품 유형별, 2017년-2031년
- 면역글로불린
- 응고인자 농축 제제
- 제VIII인자
- 제IX인자
- 제XIII인자
- 프로트롬빈 복합체 농축 제제
- 폰 필렌브란트 인자(VWF)
- 피브리노겐 농축물
- 알부민
- 프로테아제 억제제
- 기타 혈장 제품
- 시장의 매력 분석 : 제품 유형별
제7장 혈장 분획 시장 분석과 예측 : 용도별
- 서론과 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 용도별, 2017-2031년
- 신경학
- 면역학
- 혈액학
- 중환자 치료
- 호흡기 내과
- 기타
- 시장의 매력 분석 : 용도별
제8장 혈장 분획 시장 분석과 예측 : 최종사용자별
- 서론과 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 최종사용자별, 2017년-2031년
- 시장의 매력 분석 : 용도별
제9장 혈장 분획 시장 분석과 예측 : 지역별
- 주요 조사 결과
- 시장 매출 예측 : 지역별, 2017년-2031년
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 시장의 매력 분석 : 지역별
제10장 북미의 혈장 분획 시장 분석과 예측
제11장 유럽의 혈장 분획 시장 분석과 예측
제12장 아시아태평양의 혈장 분획 시장 분석과 예측
제13장 라틴아메리카의 혈장 분획 시장 분석과 예측
제14장 중동 및 아프리카의 혈장 분획 시장 분석과 예측
제15장 경쟁 구도
- 시장 경쟁 : 경쟁 매트릭스(Tier별, 기업 규모별)
- 시장 점유율 분석 : 기업별(2022년)
- 기업 개요
- CSL Limited
- Takeda Pharmaceutical Company
- Sanquin
- Biotest AG
- GRIFOLS
- Baxter International Inc.
- Kedrion
- Octapharma AG
- Taibang Biological Group Co., Ltd
LSH
Plasma Fractionation Market - Scope of Report
TMR's report on the global plasma fractionation market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global plasma fractionation market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global plasma fractionation market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the plasma fractionation market.
| Market Snapshot |
|---|
| Market Value in 2022 | US$ 24.1 Bn |
| Market Value in 2031 | US$ 42.6 Bn |
| CAGR | 6.7% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global plasma fractionation market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global plasma fractionation market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global plasma fractionation market.
The report delves into the competitive landscape of the global plasma fractionation market. Key players operating in the global plasma fractionation market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global plasma fractionation market profiled in this report.
Key Questions Answered in Global plasma fractionation Market Report:
- What is the sales/revenue generated by plasma fractionation across all regions during the forecast period?
- What are the opportunities in the global plasma fractionation market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Plasma Fractionation Market - Research Objectives and Research Approach
The comprehensive report on the global plasma fractionation market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global plasma fractionation market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global plasma fractionation market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Plasma Fractionation Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Technology, Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Plasma Fractionation Market Analysis and Forecast, 2017-2031
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Technology, /Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
6. Plasma Fractionation Market Analysis and Forecast, by Product Type
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Product Type, 2017-2031
- 6.3.1. Immunoglobulin
- 6.3.1.1. Intravenous Immunoglobulin
- 6.3.1.2. Subcutaneous Immunoglobulin
- 6.3.2. Coagulation Factor Concentrates
- 6.3.2.1. Factor VIII
- 6.3.2.2. Factor IX
- 6.3.2.3. Factor XIII
- 6.3.2.4. Prothrombin Complex Concentrates
- 6.3.2.5. Von Willebrand Factor (VWF)
- 6.3.2.6. Fibrinogen Concentrates
- 6.3.3. Albumin
- 6.3.4. Protease Inhibitors
- 6.3.5. Other Plasma Products
- 6.4. Market Attractiveness Analysis, by Product Type,
7. Plasma Fractionation Market Analysis and Forecast, by Application
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Application, 2017-2031
- 7.3.1. Neurology
- 7.3.2. Immunology
- 7.3.3. Hematology
- 7.3.4. Critical Care
- 7.3.5. Pulmonology
- 7.3.6. Others
- 7.4. Market Attractiveness Analysis, by Application
8. Plasma Fractionation Market Analysis and Forecast, by End-user
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by End-user, 2017-2031
- 8.3.1. Hospitals and Clinics
- 8.3.2. Clinical Research Laboratories
- 8.3.3. Academic Institutes
- 8.4. Market Attractiveness Analysis, by Application
9. Plasma Fractionation Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region, 2017-2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
10. North America Plasma Fractionation Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Key Findings
- 10.3. Market Value Forecast, by Product Type, 2017-2031
- 10.3.1. Immunoglobulin
- 10.3.1.1. Intravenous Immunoglobulin
- 10.3.1.2. Subcutaneous Immunoglobulin
- 10.3.2. Coagulation Factor Concentrates
- 10.3.2.1. Factor VIII
- 10.3.2.2. Factor IX
- 10.3.2.3. Factor XIII
- 10.3.2.4. Prothrombin Complex Concentrates
- 10.3.2.5. Von Willebrand Factor (VWF)
- 10.3.2.6. Fibrinogen Concentrates
- 10.3.3. Albumin
- 10.3.4. Protease Inhibitors
- 10.3.5. Other Plasma Products
- 10.4. Market Value Forecast, by Application, 2017-2031
- 10.4.1. Neurology
- 10.4.2. Immunology
- 10.4.3. Hematology
- 10.4.4. Critical Care
- 10.4.5. Pulmonology
- 10.4.6. Others
- 10.5. Market Value Forecast, by End-user, 2017-2031
- 10.5.1. Hospitals and Clinics
- 10.5.2. Clinical Research Laboratories
- 10.5.3. Academic Institutes
- 10.6. Market Value Forecast, by Country, 2017-2031
- 10.6.1. U.S.
- 10.6.2. Canada
- 10.7. Market Attractiveness Analysis
- 10.7.1. By Product Type,
- 10.7.2. By Application
- 10.7.3. By End-user
- 10.7.4. By Country
11. Europe Plasma Fractionation Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Key Findings
- 11.3. Market Value Forecast, by Product Type, 2017-2031
- 11.3.1. Immunoglobulin
- 11.3.1.1. Intravenous Immunoglobulin
- 11.3.1.2. Subcutaneous Immunoglobulin
- 11.3.2. Coagulation Factor Concentrates
- 11.3.2.1. Factor VIII
- 11.3.2.2. Factor IX
- 11.3.2.3. Factor XIII
- 11.3.2.4. Prothrombin Complex Concentrates
- 11.3.2.5. Von Willebrand Factor (VWF)
- 11.3.2.6. Fibrinogen Concentrates
- 11.3.3. Albumin
- 11.3.4. Protease Inhibitors
- 11.3.5. Other Plasma Products
- 11.4. Market Value Forecast, by Application, 2017-2031
- 11.4.1. Neurology
- 11.4.2. Immunology
- 11.4.3. Hematology
- 11.4.4. Critical Care
- 11.4.5. Pulmonology
- 11.4.6. Others
- 11.5. Market Value Forecast, by End-user, 2017-2031
- 11.5.1. Hospitals and Clinics
- 11.5.2. Clinical Research Laboratories
- 11.5.3. Academic Institutes
- 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Product Type
- 11.7.2. By Application
- 11.7.3. By End-user
- 11.7.4. By Country/Sub-region
12. Asia Pacific Plasma Fractionation Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Key Findings
- 12.3. Market Value Forecast, by Product Type, 2017-2031
- 12.3.1. Immunoglobulin
- 12.3.1.1. Intravenous Immunoglobulin
- 12.3.1.2. Subcutaneous Immunoglobulin
- 12.3.2. Coagulation Factor Concentrates
- 12.3.2.1. Factor VIII
- 12.3.2.2. Factor IX
- 12.3.2.3. Factor XIII
- 12.3.2.4. Prothrombin Complex Concentrates
- 12.3.2.5. Von Willebrand Factor (VWF)
- 12.3.2.6. Fibrinogen Concentrates
- 12.3.3. Albumin
- 12.3.4. Protease Inhibitors
- 12.3.5. Other Plasma Products
- 12.4. Market Value Forecast, by Application, 2017-2031
- 12.4.1. Neurology
- 12.4.2. Immunology
- 12.4.3. Hematology
- 12.4.4. Critical Care
- 12.4.5. Pulmonology
- 12.4.6. Others
- 12.5. Market Value Forecast, by End-user, 2017-2031
- 12.5.1. Hospitals and Clinics
- 12.5.2. Clinical Research Laboratories
- 12.5.3. Academic Institutes
- 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. China
- 12.6.2. Japan
- 12.6.3. India
- 12.6.4. Australia & New Zealand
- 12.6.5. Rest of Asia Pacific
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Product Type,
- 12.7.2. By Application
- 12.7.3. By End-user
- 12.7.4. By Country/Sub-region
13. Latin America Plasma Fractionation Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Key Findings
- 13.3. Market Value Forecast, by Product Type, 2017-2031
- 13.3.1. Immunoglobulin
- 13.3.1.1. Intravenous Immunoglobulin
- 13.3.1.2. Subcutaneous Immunoglobulin
- 13.3.2. Coagulation Factor Concentrates
- 13.3.2.1. Factor VIII
- 13.3.2.2. Factor IX
- 13.3.2.3. Factor XIII
- 13.3.2.4. Prothrombin Complex Concentrates
- 13.3.2.5. Von Willebrand Factor (VWF)
- 13.3.2.6. Fibrinogen Concentrates
- 13.3.3. Albumin
- 13.3.4. Protease Inhibitors
- 13.3.5. Other Plasma Products
- 13.4. Market Value Forecast, by Application, 2017-2031
- 13.4.1. Neurology
- 13.4.2. Immunology
- 13.4.3. Hematology
- 13.4.4. Critical Care
- 13.4.5. Pulmonology
- 13.4.6. Others
- 13.5. Market Value Forecast, by End-user, 2017-2031
- 13.5.1. Hospitals and Clinics
- 13.5.2. Clinical Research Laboratories
- 13.5.3. Academic Institutes
- 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of Latin America
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Product Type,
- 13.7.2. By Application
- 13.7.3. By End-user
- 13.7.4. By Country/Sub-region
14. Middle East & Africa Plasma Fractionation Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Key Findings
- 14.3. Market Value Forecast, by Product Type, 2017-2031
- 14.3.1. Immunoglobulin
- 14.3.1.1. Intravenous Immunoglobulin
- 14.3.1.2. Subcutaneous Immunoglobulin
- 14.3.2. Coagulation Factor Concentrates
- 14.3.2.1. Factor VIII
- 14.3.2.2. Factor IX
- 14.3.2.3. Factor XIII
- 14.3.2.4. Prothrombin Complex Concentrates
- 14.3.2.5. Von Willebrand Factor (VWF)
- 14.3.2.6. Fibrinogen Concentrates
- 14.3.3. Albumin
- 14.3.4. Protease Inhibitors
- 14.3.5. Other Plasma Products
- 14.4. Market Value Forecast, by Application, 2017-2031
- 14.4.1. Neurology
- 14.4.2. Immunology
- 14.4.3. Hematology
- 14.4.4. Critical Care
- 14.4.5. Pulmonology
- 14.4.6. Others
- 14.5. Market Value Forecast, by End-user, 2017-2031
- 14.5.1. Hospitals and Clinics
- 14.5.2. Clinical Research Laboratories
- 14.5.3. Academic Institutes
- 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Product Type,
- 14.7.2. By Application
- 14.7.3. By End-user
- 14.7.4. By Country/Sub-region
15. Competition Landscape
- 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
- 15.2. Market Share Analysis, by Company (2022)
- 15.3. Company Profiles
- 15.3.1. CSL Limited
- 15.3.1.1. Company Overview
- 15.3.1.2. Technology, Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Financial Overview
- 15.3.1.5. Strategic Overview
- 15.3.2. Takeda Pharmaceutical Company
- 15.3.2.1. Company Overview
- 15.3.2.2. Technology, Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Financial Overview
- 15.3.2.5. Strategic Overview
- 15.3.3. Sanquin
- 15.3.3.1. Company Overview
- 15.3.3.2. Technology, Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Financial Overview
- 15.3.3.5. Strategic Overview
- 15.3.4. Biotest AG
- 15.3.4.1. Company Overview
- 15.3.4.2. Technology, Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Financial Overview
- 15.3.4.5. Strategic Overview
- 15.3.5. GRIFOLS
- 15.3.5.1. Company Overview
- 15.3.5.2. Technology, Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Financial Overview
- 15.3.5.5. Strategic Overview
- 15.3.6. Baxter International Inc.
- 15.3.6.1. Company Overview
- 15.3.6.2. Technology, Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.6.4. Financial Overview
- 15.3.6.5. Strategic Overview
- 15.3.7. Kedrion
- 15.3.7.1. Company Overview
- 15.3.7.2. Technology, Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Financial Overview
- 15.3.7.5. Strategic Overview
- 15.3.8. Octapharma AG
- 15.3.8.1. Company Overview
- 15.3.8.2. Technology, Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Financial Overview
- 15.3.8.5. Strategic Overview
- 15.3.9. Taibang Biological Group Co., Ltd
- 15.3.9.1. Company Overview
- 15.3.9.2. Technology, Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Financial Overview
- 15.3.9.5. Strategic Overview
